Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the first patient has been dosed at the City of Hope National Medical Center in its global Phase 2 Clinical Trial evaluating HEPZATO™ in combination with standard of care (SOC) treatment for liver-dominant metastatic colorectal cancer (mCRC). The Phase 2 trial will evaluate the safety and efficacy of HE
Related Questions
How might this data influence Delcath's competitive positioning and potential partnership or acquisition interest from larger oncology firms?
How will the Phase 2 trial results and timeline affect Delcath's near‑term revenue outlook and share price volatility?
What are the key safety and efficacy endpoints expected from the HEPZATO™ trial, and how do they compare to existing liver‑directed therapies for metastatic colorectal cancer?